360 related articles for article (PubMed ID: 19192437)
1. A cross-sectional study of patients' perspectives on adherence to antipsychotic medication: depot versus oral.
Patel MX; de Zoysa N; Bernadt M; David AS
J Clin Psychiatry; 2008 Oct; 69(10):1548-56. PubMed ID: 19192437
[TBL] [Abstract][Full Text] [Related]
2. Depot and oral antipsychotics: patient preferences and attitudes are not the same thing.
Patel MX; De Zoysa N; Bernadt M; David A
J Psychopharmacol; 2009 Sep; 23(7):789-96. PubMed ID: 18583438
[TBL] [Abstract][Full Text] [Related]
3. Are depot antipsychotics more coercive than tablets? The patient's perspective.
Patel MX; de Zoysa N; Bernadt M; Bindman J; David AS
J Psychopharmacol; 2010 Oct; 24(10):1483-9. PubMed ID: 19304865
[TBL] [Abstract][Full Text] [Related]
4. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
[TBL] [Abstract][Full Text] [Related]
5. Adherence to depot versus oral antipsychotic medication in schizophrenic patients during the long-term therapy.
Stanković Z; Ille T
Vojnosanit Pregl; 2013 Mar; 70(3):267-73. PubMed ID: 23607237
[TBL] [Abstract][Full Text] [Related]
6. Strategies for improving treatment adherence in schizophrenia and schizoaffective disorder.
Goff DC; Hill M; Freudenreich O
J Clin Psychiatry; 2010; 71 Suppl 2():20-6. PubMed ID: 21190649
[TBL] [Abstract][Full Text] [Related]
7. Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals.
Day JC; Bentall RP; Roberts C; Randall F; Rogers A; Cattell D; Healy D; Rae P; Power C
Arch Gen Psychiatry; 2005 Jul; 62(7):717-24. PubMed ID: 15997012
[TBL] [Abstract][Full Text] [Related]
8. Adherence assessments and the use of depot antipsychotics in patients with schizophrenia.
Valenstein M; Copeland LA; Owen R; Blow FC; Visnic S
J Clin Psychiatry; 2001 Jul; 62(7):545-51. PubMed ID: 11488366
[TBL] [Abstract][Full Text] [Related]
9. Money for medication: a randomized controlled study on the effectiveness of financial incentives to improve medication adherence in patients with psychotic disorders.
Noordraven EL; Audier CH; Staring AB; Wierdsma AI; Blanken P; van der Hoorn BE; Roijen LH; Mulder CL
BMC Psychiatry; 2014 Dec; 14():343. PubMed ID: 25438877
[TBL] [Abstract][Full Text] [Related]
10. Treatment adherence in schizophrenia and schizoaffective disorder.
Goff DC; Hill M; Freudenreich O
J Clin Psychiatry; 2011 Apr; 72(4):e13. PubMed ID: 21527119
[TBL] [Abstract][Full Text] [Related]
11. Negative impact of self-stigmatization on attitude toward medication adherence in patients with psychosis.
Uhlmann C; Kaehler J; Harris MS; Unser J; Arolt V; Lencer R
J Psychiatr Pract; 2014 Sep; 20(5):405-10. PubMed ID: 25226204
[TBL] [Abstract][Full Text] [Related]
12. Psychiatrists' attitudes to maintenance medication for patients with schizophrenia.
Patel MX; Nikolaou V; David AS
Psychol Med; 2003 Jan; 33(1):83-9. PubMed ID: 12537039
[TBL] [Abstract][Full Text] [Related]
13. Nonadherence to antipsychotics: the role of positive attitudes towards positive symptoms.
Moritz S; Hünsche A; Lincoln TM
Eur Neuropsychopharmacol; 2014 Nov; 24(11):1745-52. PubMed ID: 25444234
[TBL] [Abstract][Full Text] [Related]
14. Financial incentives for improving adherence to maintenance treatment in patients with psychotic disorders (Money for Medication): a multicentre, open-label, randomised controlled trial.
Noordraven EL; Wierdsma AI; Blanken P; Bloemendaal AF; Staring AB; Mulder CL
Lancet Psychiatry; 2017 Mar; 4(3):199-207. PubMed ID: 28236956
[TBL] [Abstract][Full Text] [Related]
15. The effect of financial incentives on patients' motivation for treatment: results of "Money for Medication," a randomised controlled trial.
Noordraven EL; Wierdsma AI; Blanken P; Bloemendaal AFT; Mulder CL
BMC Psychiatry; 2018 May; 18(1):144. PubMed ID: 29793451
[TBL] [Abstract][Full Text] [Related]
16. Injections of depot antipsychotic medications in patients suffering from schizophrenia: do they hurt?
Bloch Y; Mendlovic S; Strupinsky S; Altshuler A; Fennig S; Ratzoni G
J Clin Psychiatry; 2001 Nov; 62(11):855-9. PubMed ID: 11775044
[TBL] [Abstract][Full Text] [Related]
17. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome.
Weiden PJ; Schooler NR; Weedon JC; Elmouchtari A; Sunakawa A; Goldfinger SM
J Clin Psychiatry; 2009 Oct; 70(10):1397-406. PubMed ID: 19906343
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Paliperidone Palmitate and Second-Generation Oral Antipsychotics in Terms of Medication Adherence, Side Effects, and Quality of Life.
Sağlam Aykut D
J Clin Psychopharmacol; 2019; 39(1):57-62. PubMed ID: 30566417
[TBL] [Abstract][Full Text] [Related]
19. Are we addressing the 'right stuff' to enhance adherence in schizophrenia? Understanding the role of insight and attitudes towards medication.
Beck EM; Cavelti M; Kvrgic S; Kleim B; Vauth R
Schizophr Res; 2011 Oct; 132(1):42-9. PubMed ID: 21820875
[TBL] [Abstract][Full Text] [Related]
20. Psychiatrist and patient responses to suspected medication nonadherence in schizophrenia spectrum disorders.
Hamann J; Lipp ML; Christ-Zapp S; Spellmann I; Kissling W
Psychiatr Serv; 2014 Jul; 65(7):881-7. PubMed ID: 24686753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
